Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial

Takahiko Kurasawa, Hayato Nagasawa, Mayumi Kishimoto, Koichi Amano, Tsutomu Takeuchi, Hideto Kameda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives. We examined whether the addition of another conventional disease-modifying anti-rheumatic drugs (DMARDs) to methotrexate (MTX) upon infliximab (IFX) discontinuation in well-controlled rheumatoid arthritis (RA) patients could suppress subsequent disease flare. Methods. RA patients maintaining DAS28-CRP (Disease Activity Score of 28 joints with C-reactive protein) scores < 2.6 for ≥ 6 months with IFX were randomized either to receive addition of bucillamine (BUC) to MTX (BUC + MTX group; n = 24) or not (MTX group; n = 31) upon discontinuing IFX. The primary endpoint was the flare rate within 2 years of IFX discontinuation. Results. Six patients discontinuing MTX during the study were excluded from analyses. Seventeen patients (63.0%) experienced flares in the MTX group, which was significantly reduced in the BUC + MTX group (31.8%; p = 0.045). Further, the flare rates differed significantly between remission and non-remission by a Boolean definition upon IFX discontinuation in the MTX group (40.0% vs. 91.7%, respectively; p = 0.014), but they were comparable in the BUC + MTX group. BUC treatment was interrupted in seven patients due to rash, proteinuria and incompliance. Conclusions. DMARDs combination therapy may be a better treatment strategy than MTX monotherapy for maintaining RA control after successful discontinuation of biological agents.

Original languageEnglish
Pages (from-to)561-566
Number of pages6
JournalModern Rheumatology
Volume24
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Antirheumatic Agents
Methotrexate
Rheumatoid Arthritis
Randomized Controlled Trials
Infliximab
Biological Factors
Drug Combinations
Exanthema
Proteinuria
C-Reactive Protein
Joints
bucillamine
Drug Therapy

Keywords

  • Biological agents
  • Bucillamine
  • DMARD combination
  • Flare
  • Remission

ASJC Scopus subject areas

  • Rheumatology

Cite this

Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis : An open, randomized, controlled trial. / Kurasawa, Takahiko; Nagasawa, Hayato; Kishimoto, Mayumi; Amano, Koichi; Takeuchi, Tsutomu; Kameda, Hideto.

In: Modern Rheumatology, Vol. 24, No. 4, 2014, p. 561-566.

Research output: Contribution to journalArticle

@article{206806cb110d4f24b50fd6cbe5608f06,
title = "Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial",
abstract = "Objectives. We examined whether the addition of another conventional disease-modifying anti-rheumatic drugs (DMARDs) to methotrexate (MTX) upon infliximab (IFX) discontinuation in well-controlled rheumatoid arthritis (RA) patients could suppress subsequent disease flare. Methods. RA patients maintaining DAS28-CRP (Disease Activity Score of 28 joints with C-reactive protein) scores < 2.6 for ≥ 6 months with IFX were randomized either to receive addition of bucillamine (BUC) to MTX (BUC + MTX group; n = 24) or not (MTX group; n = 31) upon discontinuing IFX. The primary endpoint was the flare rate within 2 years of IFX discontinuation. Results. Six patients discontinuing MTX during the study were excluded from analyses. Seventeen patients (63.0{\%}) experienced flares in the MTX group, which was significantly reduced in the BUC + MTX group (31.8{\%}; p = 0.045). Further, the flare rates differed significantly between remission and non-remission by a Boolean definition upon IFX discontinuation in the MTX group (40.0{\%} vs. 91.7{\%}, respectively; p = 0.014), but they were comparable in the BUC + MTX group. BUC treatment was interrupted in seven patients due to rash, proteinuria and incompliance. Conclusions. DMARDs combination therapy may be a better treatment strategy than MTX monotherapy for maintaining RA control after successful discontinuation of biological agents.",
keywords = "Biological agents, Bucillamine, DMARD combination, Flare, Remission",
author = "Takahiko Kurasawa and Hayato Nagasawa and Mayumi Kishimoto and Koichi Amano and Tsutomu Takeuchi and Hideto Kameda",
year = "2014",
doi = "10.3109/14397595.2013.844886",
language = "English",
volume = "24",
pages = "561--566",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis

T2 - An open, randomized, controlled trial

AU - Kurasawa, Takahiko

AU - Nagasawa, Hayato

AU - Kishimoto, Mayumi

AU - Amano, Koichi

AU - Takeuchi, Tsutomu

AU - Kameda, Hideto

PY - 2014

Y1 - 2014

N2 - Objectives. We examined whether the addition of another conventional disease-modifying anti-rheumatic drugs (DMARDs) to methotrexate (MTX) upon infliximab (IFX) discontinuation in well-controlled rheumatoid arthritis (RA) patients could suppress subsequent disease flare. Methods. RA patients maintaining DAS28-CRP (Disease Activity Score of 28 joints with C-reactive protein) scores < 2.6 for ≥ 6 months with IFX were randomized either to receive addition of bucillamine (BUC) to MTX (BUC + MTX group; n = 24) or not (MTX group; n = 31) upon discontinuing IFX. The primary endpoint was the flare rate within 2 years of IFX discontinuation. Results. Six patients discontinuing MTX during the study were excluded from analyses. Seventeen patients (63.0%) experienced flares in the MTX group, which was significantly reduced in the BUC + MTX group (31.8%; p = 0.045). Further, the flare rates differed significantly between remission and non-remission by a Boolean definition upon IFX discontinuation in the MTX group (40.0% vs. 91.7%, respectively; p = 0.014), but they were comparable in the BUC + MTX group. BUC treatment was interrupted in seven patients due to rash, proteinuria and incompliance. Conclusions. DMARDs combination therapy may be a better treatment strategy than MTX monotherapy for maintaining RA control after successful discontinuation of biological agents.

AB - Objectives. We examined whether the addition of another conventional disease-modifying anti-rheumatic drugs (DMARDs) to methotrexate (MTX) upon infliximab (IFX) discontinuation in well-controlled rheumatoid arthritis (RA) patients could suppress subsequent disease flare. Methods. RA patients maintaining DAS28-CRP (Disease Activity Score of 28 joints with C-reactive protein) scores < 2.6 for ≥ 6 months with IFX were randomized either to receive addition of bucillamine (BUC) to MTX (BUC + MTX group; n = 24) or not (MTX group; n = 31) upon discontinuing IFX. The primary endpoint was the flare rate within 2 years of IFX discontinuation. Results. Six patients discontinuing MTX during the study were excluded from analyses. Seventeen patients (63.0%) experienced flares in the MTX group, which was significantly reduced in the BUC + MTX group (31.8%; p = 0.045). Further, the flare rates differed significantly between remission and non-remission by a Boolean definition upon IFX discontinuation in the MTX group (40.0% vs. 91.7%, respectively; p = 0.014), but they were comparable in the BUC + MTX group. BUC treatment was interrupted in seven patients due to rash, proteinuria and incompliance. Conclusions. DMARDs combination therapy may be a better treatment strategy than MTX monotherapy for maintaining RA control after successful discontinuation of biological agents.

KW - Biological agents

KW - Bucillamine

KW - DMARD combination

KW - Flare

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=84903735257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903735257&partnerID=8YFLogxK

U2 - 10.3109/14397595.2013.844886

DO - 10.3109/14397595.2013.844886

M3 - Article

C2 - 24252035

AN - SCOPUS:84903735257

VL - 24

SP - 561

EP - 566

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 4

ER -